Blood tests to identify the initial signs of Alzheimer’s are in development. These tests are proposed for routine screenings for people above the age of 50. And it will help ensure that patients can receive the drug during the earliest stages of the disease.
Dr. Richard Oakley, the associate director of research and innovation at Alzheimer’s Society, expresses his enthusiasm, stating, “This is truly a turning point in the fight against Alzheimer’s.”
Oakley believes that donanemab and similar treatments mark the initial steps towards a future where Alzheimer’s can be managed as a long-term condition, allowing individuals to effectively handle their symptoms and lead fulfilled lives, much like those with diabetes or asthma.
Revolutionary Alzheimer’s Drug
Eli Lilly has already submitted donanemab data to the US Food and Drug Administration (FDA). And submissions to other global regulators are underway, as well.
Donanemab’s success follows another positive development in Alzheimer’s treatment. Eisai/Biogen’s lecanemab, which slows decline by 27 percent, has gained FDA approval in the US.
